# Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome

> **NCT00369629** · PHASE1 · TERMINATED · sponsor: **Northwestern University** · enrollment: 14 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT00369629
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-08-28
- **Primary completion:** 2012-07-16
- **Final completion:** 2013-06-04
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** This was planned as a phase I/II study originally, but due to a lack of funding, the phase II portion was never conducted.
- **Last updated:** 2019-08-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00369629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00369629, "Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00369629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*